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Abstract
When patients randomised to the control group of a randomised controlled trial are allowed to switch onto the
experimental treatment, intention-to-treat analyses of the treatment effect are confounded because the separation of
randomised groups is lost. Previous research has investigated statistical methods that aim to estimate the treatment
effect that would have been observed had this treatment switching not occurred and has demonstrated their
performance in a limited set of scenarios. Here, we investigate these methods in a new range of realistic scenarios,
allowing conclusions to be made based upon a broader evidence base. We simulated randomised controlled
trials incorporating prognosis-related treatment switching and investigated the impact of sample size, reduced
switching proportions, disease severity, and alternative data-generating models on the performance of adjustment
methods, assessed through a comparison of bias, mean squared error, and coverage, related to the estimation of true
restricted mean survival in the absence of switching in the control group. Rank preserving structural failure time models,
inverse probability of censoring weights, and two-stage methods consistently produced less bias than the intention-
to-treat analysis. The switching proportion was confirmed to be a key determinant of bias: sample size and censoring
proportion were relatively less important. It is critical to determine the size of the treatment effect in terms of an
acceleration factor (rather than a hazard ratio) to provide information on the likely bias associated with rank-preserving
structural failure time model adjustments. In general, inverse probability of censoring weight methods are more volatile
than other adjustment methods.
Keywords
Treatment switching, treatment crossover, survival analysis, overall survival, oncology, health technology assessment,
time-to-event outcomes, prediction
1 Introduction
Treatment switching has been the subject of several recent research papers, which have highlighted the importance
of the issue for stakeholders throughout the healthcare system.1–6 Treatment switching occurs when patients
randomised to the control group of a clinical trial are permitted to switch onto the experimental treatment at
some point during follow-up and is common in trials of oncology treatments, primarily for ethical reasons. When
treatment switching occurs, a standard intention-to-treat (ITT) analysis of groups as randomised does not measure
the comparative effectiveness of the treatments under investigation, because the control group is contaminated by
the experimental treatment. This causes problems for the estimation of the comparative treatment effect on any
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outcomes that occur after switching. This is important for regulators, clinicians, and patients. In particular, health
technology assessment (HTA) agencies around the world require that economic evaluations of treatments that
affect survival take a lifetime perspective, and thus long-term outcomes (e.g. overall survival (OS)) are critical).7–10
If an ITT analysis is used to estimate the OS treatment effect in the presence of treatment switching, inaccurate
cost-effectiveness estimates may result, and finite healthcare resources may be wasted.
We have reported on two previous simulation studies, assessing the performance of statistical methods
that allow adjustments to be made to time-to-event outcomes to account for treatment switching.2,6 In both
studies we simulated randomised controlled trials (RCTs) in which a proportion of control group patients
switched onto the experimental treatment during follow-up, with the likelihood of switching associated with
prognostic covariates. We then applied a variety of adjustment methods to determine how accurately they
estimated the ‘true’ treatment effect (i.e. the treatment effect that would have been observed in the absence of
treatment switching). We investigated scenarios that altered several parameters, such as treatment effect size and
switching proportion. Our first study6 was limited by its simplicity: in particular, the treatment effect was assumed
to be constant over time and the treatment effect received by control group patients who switched onto the
experimental treatment was the same (relative to the time for which it was taken) as that received by patients
initially randomised to the experimental group. This perfectly satisfies one of the key assumptions made by the
rank preserving structural failure time model (RPSFTM) adjustment method (the ‘common treatment effect’
assumption). In addition, our first study did not include potentially useful observational-based adjustment
methods, such as marginal structural models using inverse probability of censoring weights (referred to as
‘IPCW’ in this paper).
Our second study2 built upon our first, by incorporating a more complex data generation model which
permitted the simulation of time-dependent covariates. Observational-based adjustment methods were included,
and the sensitivity of results to violations of the ‘common treatment effect’ assumption was assessed.
Both previous studies clearly demonstrated that simple adjustment methods, such as censoring switchers at the
point of switch, and excluding switching patients from the analysis, were consistently prone to very high levels of
bias (where bias represents the difference between the ‘true’ treatment effect and the average over 1000 simulated
datasets analysed by the adjustment method), with bias often higher than that obtained using an unadjusted ITT
analysis. In both studies, randomisation-based adjustment methods, such as the RPSFTM and the iterative
parameter estimation (IPE) algorithm, produced low bias in a wide range of scenarios, provided the ‘common
treatment effect’ assumption held. However, our second study demonstrated that when the treatment effect is
strongly time dependent, and the ‘common treatment effect’ assumption does not hold, these methods produce
high levels of bias and in some circumstances may not be preferable to an ITT analysis.
Our second study showed that observational-based methods such as the IPCW and structural nested models
(SNM) are particularly sensitive to bias when the switching proportion is very high. Our simulations suggested
that the relatively small size of RCT datasets may cause these methods to work suboptimally – these methods
produced important levels of bias (approximately 5–10%) even when the switching proportion was moderate
(approximately 60%), and bias increased substantially when switching proportions increased to around 90%.
In our second study, we also tested a simple two-stage adjustment method, using a Weibull accelerated failure
time (AFT) model.2 This method performed well across the majority of scenarios, often producing less bias than
any of the other adjustment methods. Although the method was sensitive to the switching proportion, it was much
less volatile than the IPCW and SNM methods.
Both our previous studies provided valuable results. However, significant limitations were present in four key
areas: (i) We did not test any scenarios with a switching proportion of lower than 52%; (ii) the sample size
considered in our second study was limited to 500, with 1:1 randomisation to the control and experimental
groups; (iii) we simulated administrative censoring proportions only up to 21%; (iv) we only considered one
data-generating model for the simulated data. Further investigation of these issues is important. Given that
several of the adjustment methods did not perform well at high switching proportions it would be valuable
to investigate whether they perform better at lower switching proportions, particularly because observed
switching proportions vary widely and are often less than 50%.1 Metastatic oncology RCTs frequently have
sample sizes of less than 50011 and are often randomised using 2:1 or 3:1 ratios,12–15 and censoring proportions
for OS are often high.14,15
In this paper we report upon a third simulation study, with the aim of providing more complete information on
the performance of methods for adjusting RCT survival estimates in the presence of treatment switching in realistic
scenarios. We focus upon addressing the limitations associated with our previous studies. In the following section,
we briefly describe the adjustment methods. Then, we describe the methods used to conduct the current study.
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The results of the study are then presented, preceding a discussion of these, their implications, and the limitations
of the study.
2 Adjustment methods
Adjustment methods have been summarised several times before1–6 and are described only briefly here.
The different switching adjustment methods are grouped into simple methods (those which have been used
regularly in the past)6 and more complex methods. Further, the more complex methods are classified as
‘observational-based’ methods and ‘randomisation-based’ methods (sometimes termed ‘randomisation-based
efficacy estimators’16).
2.1 Simple methods
2.1.1 Intention to treat. An ITT analysis compares groups as randomised, without adjusting for treatment
switching.
2.1.2 Per protocol (PP) – Excluding and censoring switchers. PP analyses involve analysing patients according to the
treatment actually received. In the case of treatment switching, patients are censored at the point of switch
(PPcens) or are excluded entirely from the analysis (PPexc). These analyses may disrupt the between-group
balance achieved through randomisation and are therefore prone to selection bias – particularly if switching
is associated with prognostic factors.16,17
2.2 Complex methods
2.2.1 Observational-based complex methods
2.2.1.1 IPCW. IPCW can be used within a marginal structural model (MSM) to estimate a treatment effect in
the presence of informative censoring. In the context of treatment switching, patients are censored at the time of
switch, and remaining observations are weighted using information on baseline and time-dependent patient
characteristics. Through this weighting mechanism, the IPCW approach attempts to avoid the selection bias
associated with a simple PP censoring analysis.
Stabilised weights estimated for each individual for each time interval (t), as specified by Hernan et al.18 are:
W^ðtÞ ¼
Yt
k¼0
Pr CðkÞ ¼ 0j C k 1ð Þ ¼ 0, A k 1ð Þ, V, T4 k 
Pr CðkÞ ¼ 0j Cðk 1Þ ¼ 0, A k 1ð Þ, L kð Þ, T4 k  ð1Þ
where CðkÞ is an indicator function demonstrating whether or not informative censoring (switching) had occurred
at the end of interval k, and C k 1ð Þ denotes censoring history to the end of the previous interval. A k 1ð Þ
denotes an individual’s treatment history up to the end of the previous interval, and V is an array of an individual’s
baseline covariates. L kð Þ denotes the history of an individual’s time-dependent covariates measured at or prior to
the beginning of interval k. The numerator of equation (1) represents the probability of an individual remaining
uncensored (i.e. not switched) at the end of interval k given that he or she was uncensored at the end of the
previous interval k 1ð Þ, conditional on baseline characteristics and treatment history. The denominator of
equation (1) represents that same probability, but differs from the numerator because it is conditional on
baseline characteristics, treatment history and time-dependent characteristics. When the cause of informative
censoring is treatment switching, past treatment history is removed from the weight because when switching
occurs the individual is censored.
Stabilised weights are incorporated within an MSM to estimate a treatment effect adjusted for informative
censoring (treatment switching). For instance, an adjusted Cox hazard ratio (HR) can be estimated by fitting a
time-dependent Cox model19 to a dataset in which switching patients are artificially censored, which includes
baseline covariates and uses the time-varying stabilised weights for each patient and each time interval.20
For the IPCW to appropriately adjust for any selection bias created by informative censoring, data must be
available on all prognostic factors for mortality that independently predict informative censoring (the untestable
‘no unmeasured confounders’ assumption).21,22 In addition, models for switching and survival must be correctly
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specified,23 and the method is not applicable if there are any covariates which ensure (i.e. the probability equals 1)
that treatment switching will occur.18,22,24
2.2.1.2 Two-stage estimation. In our previous simulation study, we considered a simple two-stage method for
adjusting for treatment switching, designed in accordance with the type of switching often observed in metastatic
oncology RCTs.2 Usually switching is permitted only after disease progression (often because progression-free
survival is used as the primary trial outcome). In this case, disease progression can be used as a secondary baseline
for patients in the control group and post-progression data on these patients can be analysed as an observational
dataset, under the assumption that at the time of disease progression all patients are at a similar state of disease.
A treatment effect ( ) attributed to treatment switching can then be estimated by fitting an AFT model to this
data, including covariates for prognostic factors measured at the secondary baseline and a time-varying covariate
indicating treatment switch. In our previous study, we tested a Weibull model, but other AFT models, such as the
Generalised Gamma, could be used – the performance of these different models is tested in the current study.
These models would be expected to produce an accurate estimate of the treatment effect received by patients who
switched provided the model fits the data, there are ‘no unmeasured confounders’ at the point of the secondary
baseline and that switching occurs soon after the secondary baseline. Counterfactual survival times (Ui), that is
survival times that would have been observed in the absence of treatment switching, can then be obtained using
Ui ¼ TAi þ e 0TBi ð2Þ
where TAi represents the time spent on control treatment, TBi represents the time spent on the new intervention and
e 0 represents the acceleration factor (AF) in switchers – the amount by which an individual’s expected survival
time is increased by treatment.
Robins and Greenland21 and Yamaguchi and Ohashi25 previously used a similar approach to adjust for treatment
switches, but utilised an observational-based SNM to estimate the treatment effect in switchers, rather than a less
complex AFT model as described here. The observational-based SNM utilises the ‘no unmeasured confounders’
assumption to estimate the causal effect of a time-dependent treatment, making use of data on patient characteristics
measured at baseline and through time.26 However, our previous study demonstrated that in the context of an RCT,
in which patient and event numbers may be small, the observational-based SNM method is prone to poor
convergence and performance.2
The simplified two-stage method is theoretically inferior to the observational-based SNM because it only uses
time-dependent data collected at the time of disease progression (the ‘secondary baseline’) and therefore makes the
strong assumption that there is no time-dependent confounding beyond disease progression. It also requires that a
parametric model that adequately fits the data can be identified. However, owing to the fact that the simplified
two-stage approach uses less data than the observational SNM, our previous study suggested that it led to better
convergence.2 It also produced low bias, which would be expected in circumstances where treatment switching
occurs soon after the secondary baseline. Due to its superior performance in our previous study we include the
simplified two-stage method in the present study but not the observational SNM approach.
2.2.2 Randomisation-based efficacy estimators
2.2.2.1 RPSFTM. The RPSFTM method represents a SNM approach designed specifically for an RCT
context.27,28 In this study, we consider the simple one-parameter version of this model. The RPSFTM uses a
counterfactual framework to estimate the causal effect of the treatment in question, but relies only upon the
randomisation of the trial, treatment history and observed survival times to identify the treatment effect. The
method splits the observed event time (Ti) for each patient into two, that is the time spent on the control treatment
(TAi) and the time spent on the intervention treatment (TBi). The RPSFTM method relates Ti to the counterfactual
event time (Ui) with the same model as presented in equation (2). However, under the RPSFTM approach, the
value of  is estimated using a grid search called g-estimation.29 For each value of  , equation (2) is used
to estimate Ui, and the true value of  is that for which Uð Þ is independent of randomised groups, based
upon a g-test.26 The g-test tests the hypothesis that the counterfactual survival curves are identical in the two
treatment groups, with the point estimate of  being that for which the test (z) statistic equals zero. A range of tests
(e.g. log-rank, Cox, exponential, Weibull) could be used for this purpose.6
The one-parameter RPSFTM is reliant upon the ‘common treatment effect’ assumption, which requires
that the relative treatment effect of the intervention is equal for all patients, no matter when the intervention
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is received – this may be problematic in the context of an oncology RCT if switching is only permitted after disease
progression, as progressive disease may conceivably alter capacity to benefit. The RPSFTM also assumes that
randomisation has worked successfully, such that there are no differences between randomised groups, apart from
the treatment allocated.
2.2.2.2 IPE algorithm. Branson and Whitehead extended the RPSFTM method, developing a novel
parametric estimation procedure, in place of g-estimation.30 A parametric failure time model is fitted to the
unadjusted survival data to obtain an initial estimate of  . Using this, the observed failure times of switching
patients are re-estimated through the counterfactual survival time model presented in equation (2), and the
treatment groups are then compared again using the parametric model. This produces an updated estimate of
 , and the process of re-estimating survival times for switching patients is repeated. This iterative process is
continued until the process converges (defined by the authors as when the new estimate for expð Þ is within 10-
5 of the previous estimate).30
The IPE procedure requires the same assumptions as the RPSFTM method, and additionally Ui must follow a
parametric failure time distribution.
3 Simulation study design
We simulated independent datasets in which treatment switching was permitted, and in which the true survival
differences between treatment options were known. We then applied each of the switching adjustment methods
and compared their bias, mean squared error and coverage in estimating the true restricted mean survival time in
the control group. We designed the study such that the data simulated reflected data typically observed in clinical
trials in the advanced/metastatic cancer disease area, building upon the methods used in our previous study.
The simulation study was conducted using Stata software, version 11.2.31
3.1 Underlying survival times
We used a similar simulation approach to that used in our previous study.2 A joint survival and longitudinal model
was used to simultaneously generate a continuous time-dependent covariate (referred to as ‘biomarker’)
and survival times.32 The biomarker influenced both survival and the probability of treatment switching and
was influenced by treatment received. Within the data-generating joint model, the longitudinal model for the
biomarker value for the ith patient at time t was
biomarkeri tð Þ ¼ 0i þ 1ðtÞ þ 2ðtÞ trti þ 3badprogi ð3Þ
where
0i  Nð0, 20Þ
0i is the random intercept, 1 the slope against time for a patient in the control group and 1 þ 2 the slope
against time for a patient in the experimental treatment group. 3 is the change in the intercept for a patient with a
poor prognosis (referred to as ‘badprog’) compared to a patient with a good prognosis, trti is a binary covariate
that equals 1 when the patient is in the experimental group and 0 otherwise, and badprogi is a binary covariate that
equals 1 when a patient has poor prognosis at baseline, and 0 otherwise.
In our previous study, we simulated survival times using a Weibull baseline distribution and the biomarker
model changed linearly with log time (rather than time shown in equation (3)). This allowed use of the inversion
simulation method described by Bender et al.,33 which is a computationally simple method to implement, with all
required formulae having closed form solutions.
In order to simulate survival times from a more complex underlying distribution, to more closely reflect those
seen in real datasets, in this study we used the general survival simulation framework described by Crowther and
Lambert,32 which uses a combination of numerical integration and root finding to simulate survival dependent on
a time-varying biomarker. In particular, we assumed a two-component mixture Weibull baseline survival function
to incorporate the desired flexibility. This can be written as
s0 tð Þ ¼ p exp 1t1ð Þ þ 1 pð Þ exp 2t2ð Þ ð4Þ
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where 1, 24 0 and 1, 24 0 are scale and shape parameters, respectively. The mixture parameter, p, with
0  p  1, represents the contribution of the first Weibull to the OS model, and 1 p represents the
contribution of the second Weibull. The related baseline hazard function is
h0 tð Þ ¼ 11pt
11exp 1t1ð Þ þ 22 1 pð Þt21exp 2t2ð Þ
p exp 1t1ð Þ þ 1 pð Þ exp 2t2ð Þ ð5Þ
The linear predictor of the survival model was incorporated as follows
hi tð Þ ¼ h0 tð Þ exp½XiðtÞðtÞ ð6Þ
where
XiðtÞðtÞ ¼ 1 trtið Þ þ  t trtið Þ þ 2badprogi þ  biomarkeri tð Þð Þ ð7Þ
1 is the baseline log HR intercept,  the rate at which the treatment effect changes with time, 2 is the impact of
poor prognosis and  is the coefficient of the biomarker level.
Simulating using a mixture model allows us to simulate complex hazard functions that could not be produced
using one Weibull model. The result is a hazard function that does not represent that associated with any standard
parametric distribution. This is important because there is no reason to expect that real-world survival data will
follow standard parametric distributions, and also because simulating complex hazard functions means that none
of the switching adjustment methods should be advantaged due to underlying assumptions. To further investigate
the impact of the data-generating mechanism on the performance of adjustment methods, in this study we tested
additional scenarios in which mixture Gompertz models were used in place of mixture Weibull models.
In the ‘base case’ (Scenario 1) simulation, the parameter values for the mixture Weibull survival model and the
longitudinal biomarker model were
0 ¼ 20, 20 ¼ 1, 1 ¼ 15, 2 ¼ 8, 3 ¼ 10, 1 ¼ 0:75, 2 ¼ 0:5,
 ¼ 0:02, 1 ¼ 1:8, 1 ¼ 2:1, 2 ¼ 0:1, 2 ¼ 0:5, p ¼ 0:7,  ¼ 0:3
An example from a single simulated dataset of the Kaplan–Meier curves produced by the simulation model (in
the absence of treatment switching) using these parameter values is presented in Figure 1(a), with a non-parametric
smoothed estimate of the associated hazard function illustrated in Figure 1(b). This demonstrates that we
simulated a hazard function that was initially low, then steadily increased before decreasing towards the end of
the trial follow-up. We believe that this is representative of the types of hazards that would be expected within a
metastatic oncology RCT setting: the initial hazard is likely to be low, reflecting inclusion criteria that dictate that
patients with the worst prognosis are excluded. The hazard is then likely to rise, reflecting the seriousness of the
disease, before falling in the longer term as those who remain alive are of relatively better prognosis.
3.2 Treatment effect in the experimental group
We cannot summarise the treatment effect experienced in the experimental group using a single value, because our
hazard function includes ‘t’ terms. As demonstrated by Figure 1(b), the treatment effect (as observed by the
difference between the hazard functions) initially increases during the period of greatest hazard, before falling
in the longer term. We believe that this is representative of a realistic treatment effect, which falls in the longer term
when the initial treatment effect may have worn off, and when only better prognosis patients remain alive.
3.3 Treatment effect in switchers
The treatment effect applied to patients who switched from the control group to the experimental treatment was
calculated in the same way as for our previous study.2 The baseline treatment effect was applied to switchers, but
was multiplied by a factor (!) such that the effect received was equal to or lower than the average effect received by
experimental group patients. The magnitude of ! was varied across scenarios to represent relative reductions in the
average treatment effect of 0 and 20%. This allowed us to test scenarios in which the ‘common treatment effect’
assumption did and did not hold.
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3.4 The switching mechanism
Patients were only at risk of switching during the three consultations immediately following disease progression –
switching was not permitted before disease progression had occurred, to reflect the treatment switching typically
seen in metastatic cancer trials.1 In addition, switching was only permitted in patients who were randomly assigned
a value of ‘1’ for a ‘choice’ variable. During this ‘at-risk’ period, the probability of switching declined for each
individual patient with each simulated consultation, which were assumed to occur every 21 days. The probability
of switching during the ‘at-risk’ period was calculated using a logistic function and depended upon the biomarker
value at the time of disease progression and the time of progression itself. The probability of switching was highest
if the biomarker value was high at the time of disease progression, and if time to progression was high. Both these
factors indicate that patients with a relatively long progression-free survival period were more likely to switch.
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Figure 1. (a) Overall survival Kaplan–Meier from one simulated dataset Scenario 1: No switching, (b) hazard function from
one simulated dataset Scenario 1: No switching. Note: trtrand¼ 0 represents the control group; trtrand¼ 1 represents the
experimental group.
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In the base case, switching probabilities were set such that approximately 40% of control group patients switched
treatments. Switching probabilities were increased (or decreased) for all patients with a ‘choice’ covariate value of
‘1’ during their ‘at-risk’ period in order to investigate scenarios with higher (or lower) switching proportions. A
variable for choice was incorporated because in most RCTs data on patient preference for switching are not
collected, and for methods such as the IPCW this could represent an unmeasured confounder. Eighty per cent of
patients were assigned a value of ‘1’ and 20% were assigned a value of ‘0’. Further details on the probability of
switching in different simulated groups are presented in Appendix 1.
3.5 Scenarios investigated
The simulated data-generating mechanism had several variables for which values had to be assumed. These are
listed in Appendix 2. The variables altered within our main set of scenarios related to:
. Switch proportion: low (approximately 16% of control group), moderate (approximately 40% of control
group);
. Treatment effect: moderate (average HR under the incorrect assumption of proportional hazards,
approximately 0.75), high (average HR approximately 0.50);
. Relative treatment effect decrement received by switchers: 0%, 20%;
. Severity of disease: moderate severity (restricted mean survival in control group approximately 365 days,
administrative censoring proportion approximately 55%); severe (restricted mean survival in control group
approximately 285 days, administrative censoring proportion approximately 15%);
. Sample size: moderate (n¼ 500); small (n¼ 300), both with 2:1 randomisation in favour of the experimental
treatment;
. Data-generating model: two-component mixture Weibull baseline hazard function; two-component mixture
Gompertz baseline hazard function.
Varying the switch proportion, the treatment effect size, the commonality of the treatment effect and disease
severity resulted in 16 ‘base’ scenarios. Additionally, testing the impact of sample size and the data-generating
model resulted in 64 scenarios. Finally, we re-ran four selected scenarios to replicate the high switching
proportions simulated in our previous study,2 in order to assess the consistency of the results between the two
studies. In total 68 scenarios were run. One thousand simulations were run for each scenario.
3.6 Performance measures
As was the case in our previous study, the time dependency of the treatment effect meant that it was not possible to
produce a single ‘true’ HR or AF that the results of the adjustment methods could be compared to. Instead, we
used restricted mean survival time as our true value upon which to base our performance measures. This is useful
from a HTA perspective because for economic evaluation it is necessary to estimate mean survival times, in order
that resource allocation decisions can be made based upon analyses that consider the impact of treating entire
disease populations.
In our previous study, we were able to integrate the survivor functions associated with our simulated
survival data in order to calculate the true restricted mean survival time for the control group for each
scenario. However, the equation for the survival function was not analytically tractable in the current study.
Instead, for each scenario we simulated data for 1,000,000 patients without incorporating treatment switching and
estimated mean survival at 18 months (the administrative censoring time in the simulated datasets). We used
this as the ‘truth’ upon which to base performance measures. Because this value is the product of a simulation
rather than a calculation it is prone to error, but this is likely to be extremely minimal given the large number of
patients simulated.
We evaluated the performance of the switching adjustment methods according to the bias in their estimate
of the true survival (restricted mean at 18 months) for the control group. Bias () was measured by the difference
between the true restricted mean () and the estimated restricted mean (^). Percentage bias was calculated as

 100.34 The mean squared error (MSE) was also calculated to provide information on the variability of the
estimates obtained using the different adjustment methods in combination with their bias. The standard error was
that associated with the mean of the restricted means estimated by each adjustment method over the 1000
simulations run for each scenario.
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The coverage of each method was also calculated, defined as the proportion of simulations where the 95%
confidence intervals (CIs) of the restricted mean estimated by each method contained the true restricted mean. We
also calculated the proportion of times that each method resulted in an estimate of the treatment effect (i.e. the
proportion of times they converged). Where methods did not converge the bias and coverage performance
measures were calculated based upon simulations in which convergence did occur.
3.7 Adjustment methods included
We included the following methods in the simulation study: ITT, Exclude switchers (PPexc), Censor at switch
(PPcens), IPCW, IPCW excluding the ‘choice’ covariate (IPCWn), RPSFTM, IPE with a Weibull model (IPE),
IPE with an exponential model (IPEexp), two-stage Weibull model (Weib2m), two-stage generalised Gamma
model (Gam2m).
For the RPSFTM method, we used a Cox test within the g-estimation procedure, and for the IPE algorithm we
tested the use of exponential and Weibull models within the estimation procedure, in order to assess whether the
performance of the method is sensitive to this. The Stata command strbee was used to apply the RPSFTM and IPE
methods,35 and baseline covariates were included in the models. For the IPCW method, we used stabilised weights
used a similar approach to that described by Fewell et al.36 We included two versions – one in which all covariates
were included in the relevant models, and one in which the ‘choice’ covariate was excluded – in order to test the
sensitivity of the method to the availability of this covariate.
We applied the two-stage method using Weibull and generalised Gamma models, so that the performance of
different AFT models could be compared. We fitted these models to control group patients using disease progression
as the secondary baseline time point, and included covariates for switching, baseline prognosis group, baseline
biomarker value, time-to-disease progression, biomarker value at disease progression and the ‘choice’ covariate.
It has been shown that informative censoring is problematic for adjustment methods that estimate counterfactual
survival times,37–39 and therefore RPSFTM, IPE and two-stage methods incorporated recensoring, whereby the
counterfactual survival time Uið Þ was recensored at the minimum of the administrative censoring time Ci and
Ci exp . Uið Þ was then replaced by the censoring time of the counterfactual event time Di  ð Þ if Di  ð Þ5 Uið Þ.
For each of the methods applied, the techniques used to derive mean survival times restricted to 18 months were
similar to those used in our previous study.2 For the ITT, PPexc and PPcens analyses, Stata’s stci command
was used to calculate the area under the Kaplan–Meier survivor function at 18 months for the specified group. For
the IPCW, RPSFTM, IPE and two-stage estimation analyses, the ‘survivor function’ approach was used.2 First,
the inverse of the estimated treatment effect was applied to the experimental group hazard function (modelled
using a flexible parametric model) to obtain the adjusted control group hazard function. For the IPCW methods,
the treatment effect used was the IPCW HR, and for the RPSFTM, IPE and two-stage methods, the HR associated
with the adjustment (estimated using a flexible parametric model comparing observed experimental group survival
times and adjusted control group survival times) was used. From this, the control group survivor function was
derived, allowing mean survival at 18 months to be calculated. CIs were derived in the same way, except the inverse
of the 95% CIs of the estimated treatment effect were applied to the experimental group hazard function.
4 Results
We present detailed results from eight scenarios that illustrate the key findings. First we report key results in
scenarios that involved moderate (approximately 50%) switching proportions, followed by key results in scenarios
that involved low (approximately 20%) switching proportions. We then summarise the extent to which the eight
scenarios focussed upon reflect the results of the eight other base scenarios completed. Finally, we summarise the
results of the additional scenarios run – those that tested the sensitivity of the results to the sample size, the data-
generating model and those that tested extreme high switching proportions.
A summary table describing the characteristics of each scenario is presented in Appendix 3, and Appendix 4
presents the percentage bias for each adjustment method across all scenarios.
4.1 Scenarios with moderate switching proportions
Tables 1 and 2 present detailed results from Scenarios 1, 3, 9 and 11. These are illustrative of the results of
scenarios in which the switching proportion simulated was approximately 58–61% of at-risk patients (30–44%
of all control group patients).
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Table 1. Scenarios 1 and 3 – results.
Scenario details Method
Mean
estimate
SE of
mean
95% Confidence
interval
Bias
Percent
bias MSE
Coverage
(%)
Successful
estimation (%)Lower Upper
Scenario number: 1
True mean survival:
Control: 0.56
Experimental: 0.79
Mean switch: 58.26%
True ave. HR: 0.51
Mean censored: 13.59%
Treatment effect:
20% decrement
ITT 0.60 0.03 0.55 0.66 0.05 8.22 0.0029 65.40 100.00
PPExc 0.50 0.04 0.43 0.58 -0.06 -9.94 0.0044 66.40 100.00
PPcens 0.65 0.04 0.57 0.74 0.10 17.66 0.0114 36.10 100.00
IPCW 0.54 0.03 0.47 0.63 -0.01 -2.30 0.0013 97.60 100.00
IPCWn 0.54 0.03 0.47 0.63 -0.01 -2.46 0.0012 97.40 100.00
Weib2m 0.56 0.03 0.54 0.58 0.00 0.62 0.0009 55.60 100.00
Gam2m 0.56 0.03 0.54 0.58 0.00 0.54 0.0009 56.30 100.00
RPSFTM 0.55 0.03 0.49 0.62 -0.01 -1.40 0.0011 94.70 100.00
IPE 0.55 0.03 0.48 0.62 -0.01 -1.70 0.0012 94.20 100.00
IPEexp 0.55 0.03 0.48 0.62 -0.01 -1.90 0.0012 93.90 100.00
Scenario number: 3
True mean survival:
Control: 0.64
Experimental: 0.74
Mean switch: 61.20%
True ave. HR: 0.76
Mean censored: 15.03%
Treatment effect:
20% decrement
ITT 0.66 0.03 0.60 0.72 0.02 2.94 0.0014 91.90 100.00
PPExc 0.61 0.05 0.51 0.70 -0.03 -5.37 0.0034 86.50 100.00
PPcens 0.78 0.05 0.69 0.88 0.14 22.13 0.0223 14.70 100.00
IPCW 0.65 0.04 0.55 0.76 0.01 1.19 0.0018 98.40 100.00
IPCWn 0.64 0.04 0.55 0.74 0.00 0.51 0.0015 98.60 100.00
Weib2m 0.64 0.03 0.61 0.67 -0.00 -0.42 0.0012 52.60 100.00
Gam2m 0.64 0.03 0.61 0.67 -0.00 -0.52 0.0012 53.70 99.90
RPSFTM 0.63 0.04 0.56 0.71 -0.01 -1.40 0.0018 93.30 100.00
IPE 0.63 0.04 0.56 0.71 -0.01 -1.69 0.0019 92.80 100.00
IPEexp 0.63 0.04 0.56 0.71 -0.01 -1.79 0.0019 92.50 100.00
Table 2. Scenarios 9 and 11 – results.
Scenario details Method
Mean
estimate
SE of
mean
95% Confidence
interval
Bias
Percent
bias MSE
Coverage
(%)
Successful
estimation (%)Lower Upper
Scenario number: 9
True mean survival:
Control: 0.56
Experimental: 0.79
Mean switch: 58.27%
True ave. HR: 0.51
Mean censored: 13.74%
Treatment effect:
0% decrement
ITT 0.61 0.03 0.55 0.67 0.05 9.83 0.0039 56.20 100.00
PPExc 0.50 0.04 0.42 0.57 -0.06 -10.54 0.0049 63.40 100.00
PPcens 0.65 0.04 0.57 0.74 0.10 17.16 0.0109 40.10 100.00
IPCW 0.54 0.03 0.47 0.63 -0.01 -2.27 0.0013 98.00 100.00
IPCWn 0.54 0.03 0.47 0.63 -0.01 -2.49 0.0012 97.70 100.00
Weib2m 0.56 0.03 0.54 0.58 0.00 0.48 0.0009 55.90 100.00
Gam2m 0.56 0.03 0.54 0.58 0.00 0.42 0.0009 56.70 100.00
RPSFTM 0.56 0.04 0.49 0.63 0.00 -0.01 0.0012 95.10 100.00
IPE 0.55 0.03 0.49 0.63 0.00 -0.31 0.0012 95.30 100.00
IPEexp 0.55 0.03 0.49 0.62 0.00 -0.55 0.0012 94.90 100.00
Scenario number: 11
True mean survival:
Control: 0.64
Experimental: 0.74
Mean switch: 60.90%
True ave. HR: 0.76
Mean censored: 15.09%
Treatment effect:
0% decrement
ITT 0.66 0.03 0.60 0.73 0.02 3.48 0.0016 89.10 100.00
PPExc 0.61 0.05 0.51 0.70 -0.04 -5.46 0.0036 84.60 100.00
PPcens 0.78 0.05 0.69 0.88 0.14 21.74 0.0218 16.20 100.00
IPCW 0.65 0.04 0.55 0.76 0.01 1.29 0.0020 98.00 100.00
IPCWn 0.65 0.04 0.55 0.74 0.00 0.60 0.0017 98.30 100.00
Weib2m 0.64 0.04 0.61 0.66 -0.00 -0.61 0.0013 51.30 100.00
Gam2m 0.64 0.04 0.61 0.66 -0.00 -0.71 0.0013 51.20 100.00
RPSFTM 0.64 0.04 0.56 0.72 0.00 -0.77 0.0020 92.10 100.00
IPE 0.63 0.04 0.56 0.71 -0.01 -1.06 0.0020 91.20 100.00
IPEexp 0.63 0.04 0.56 0.71 -0.01 -1.17 0.0021 90.70 100.00
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The characteristics of Scenario 1, with regard to survival times, switch proportion, treatment effect and
censoring proportion are described in Table 1. To summarise, this scenario incorporated a moderate switch
proportion, a large treatment effect, a low censoring proportion and violated the common treatment effect
assumption. It is important to note that the average HR is included in Tables 1 to 4 for illustrative purposes
only, to give an idea of the size of the treatment effect – it was estimated by generating scenario-specific survival
data for a large number of patients (1,000,000) without applying switching, and by fitting a Cox model to this.
However, given that the proportional hazards assumption does not apply in our simulated datasets, this estimate
of the treatment effect is prone to error.
As expected, in Scenario 1 the ITT analysis overestimated the true, unconfounded control group restricted
mean survival time, equivalent to a percentage bias of 8.22%. Simple adjustment methods (PPexc, PPcens)
produced substantially higher percentage bias than the ITT analysis. The IPCW and the IPCWn both
underestimated mean survival in the control group (hence over-estimated the treatment effect) but produced
lower bias than the ITT analysis (percentage bias -2.30 and -2.46% for IPCW and IPCWn, respectively). The
RPSFTM, IPE and IPEexp produced similarly low levels of bias (percentage bias -1.40, -1.70 and -1.90%,
respectively), under-estimating mean survival in the control group but producing lower bias than the ITT and
IPCW analyses. The Weib2m and Gam2m methods produced less bias than all other methods, resulting in very
low percentage bias of 0.62 and 0.54%, respectively.
The only substantive difference between Scenario 1 and Scenario 3 was that the treatment effect was smaller in
Scenario 3 (see Table 2). Due to this, the relative bias associated with each of the adjustment methods generally
marginally decreased. However, the best performing adjustment methods remained the same – the Weib2m and
Gam2m produced least bias (percentage bias -0.42 and -0.52%, respectively). In contrast, in this scenario the
IPCW and IPCWn produced lower bias than the RPSFTM, IPE and IPEexp (percentage bias 1.19 and 0.51%
compared to -1.40, -1.69 and -1.79%, respectively). The simple adjustment methods again produced substantially
higher levels of bias. Due to the lower treatment effect the ITT analysis produced lower percentage bias than in
Scenario 1, but still produced higher bias than all adjustment methods except PPcens and PPexc.
Table 2 presents detailed results of Scenario 9 and Scenario 11. Scenario 9 is approximately equivalent to
Scenario 1 and Scenario 11 is approximately equivalent to Scenario 3, except the common treatment effect
assumption holds. This has an important impact upon the results of the randomisation-based adjustment
methods. While the Weib2m and Gam2m methods continued to produce similarly low levels of bias, the
percentage bias associated with the RPSFTM/IPE methods reduced. The IPCW and IPCWn methods
produced similar levels of bias to those found in Scenarios 1 and 3. The ITT analysis again produced higher
bias than all adjustment methods except PPcens and PPexc.
Tables 1 and 2 show a substantial difference in the levels of coverage and MSE achieved by each of the
adjustment methods. It is important to note the low levels of coverage achieved by the Weib2m and Gam2m
(ranging from 51.20 to 56.70%) – particularly because these produce low levels of bias. In contrast, the IPCW
method produced higher levels of coverage (97.40–98.60%) in Scenarios 1, 3, 9 and 11, indicating relatively wide
CIs. The RPSFTM, IPE and IPEexp approaches led to similarly high levels of coverage (ranging from 90.70 to
95.30%).
The two-stage adjustment methods also produced poor coverage in our previous study,2 because CIs for mean
counterfactual survival times were estimated by using the 95% CIs for  0 in equation (2). This only takes into
account the uncertainty in the treatment effect itself – it does not take into account the uncertainty in the
underlying survival distribution. In reality, if a two-stage approach were to be taken, uncertainty around mean
survival estimates would need to be taken into account using bootstrapping.
The MSE results suggest that the levels of variability associated with the different adjustment methods were
generally similar relative to the bias levels – i.e. higher levels of bias were generally associated with higher MSEs.
Successful estimation was achieved with all of the adjustment methods across Scenarios 1, 3, 9 and 11, with the
Gam2m method failing to converge in 0.1% of simulations in Scenario 3. The IPCW and IPCWn methods failed
to converge in one of the weighting regressions in several simulations, but estimations were still obtained from
these. Restricting the results of these methods only to simulations in which full convergence was achieved in each
of the regression models had only a minor impact on their performance – as described in Appendix 5.
4.2 Scenarios with low switching proportions
Tables 3 and 4 present detailed results from Scenarios 5, 7, 13 and 15. These are illustrative of the results of
scenarios in which the switching proportion simulated was approximately 23–26% of at-risk patients (13–18% of
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Table 4. Scenarios 13 and 15 – results.
Scenario details Method
Mean
estimate
SE
of mean
95% Confidence
interval
Bias
Percent
bias MSE Coverage (%)
Successful
estimation (%)Lower Upper
Scenario number: 13
True mean survival:
Control: 0.56
Experimental: 0.79
Mean switch: 23.76%
True ave. HR: 0.51
Mean censored: 13.52%
Treatment effect:
0% decrement
ITT 0.58 0.03 0.52 0.63 0.02 3.99 0.0013 88.40 100.00
PPExc 0.53 0.03 0.47 0.59 -0.03 -5.19 0.0017 80.80 100.00
PPcens 0.58 0.03 0.52 0.64 0.02 3.73 0.0014 90.90 100.00
IPCW 0.53 0.03 0.47 0.61 -0.02 -4.02 0.0014 94.90 100.00
IPCWn 0.53 0.03 0.47 0.61 -0.02 -4.05 0.0014 95.00 100.00
Weib2m 0.56 0.03 0.55 0.57 0.00 0.60 0.0008 31.00 100.00
Gam2m 0.56 0.03 0.55 0.57 0.00 0.58 0.0008 31.70 99.70
RPSFTM 0.56 0.03 0.49 0.63 0.00 0.11 0.0009 97.90 100.00
IPE 0.56 0.03 0.49 0.63 0.00 0.01 0.0009 97.90 100.00
IPEexp 0.56 0.03 0.49 0.63 0.00 -0.06 0.0009 98.20 100.00
Scenario number: 15
True mean survival:
Control: 0.64
Experimental: 0.74
Mean switch: 25.61%
True ave. HR: 0.76
Mean censored: 15.04%
Treatment effect:
0% decrement
ITT 0.65 0.03 0.59 0.71 0.01 1.43 0.0011 94.90 100.00
PPExc 0.62 0.04 0.55 0.69 -0.02 -3.68 0.0019 89.10 100.00
PPcens 0.68 0.04 0.60 0.75 0.04 5.51 0.0025 86.20 100.00
IPCW 0.64 0.04 0.56 0.72 0.00 -0.76 0.0013 97.70 100.00
IPCWn 0.64 0.04 0.56 0.72 -0.01 -0.83 0.0013 97.80 100.00
Weib2m 0.64 0.03 0.63 0.66 0.00 0.02 0.0011 33.50 100.00
Gam2m 0.64 0.03 0.63 0.66 -0.00 -0.00 0.0011 33.10 99.70
RPSFTM 0.64 0.04 0.56 0.72 0.00 -0.45 0.0013 96.50 100.00
IPE 0.64 0.04 0.56 0.72 0.00 -0.55 0.0013 96.40 100.00
IPEexp 0.64 0.04 0.56 0.72 0.00 -0.58 0.0013 96.40 100.00
Table 3. Scenarios 5 and 7 – results.
Scenario details Method
Mean
estimate
SE of
mean
95% Confidence
interval
Bias
Percent
bias MSE
Coverage
(%)
Successful
estimation (%)Lower Upper
Scenario number: 5
True mean survival:
Control: 0.56
Experimental: 0.79
Mean switch 23.78%
True ave. HR: 0.51
Mean censored: 13.42%
Treatment effect:
20% decrement
ITT 0.58 0.03 0.52 0.63 0.02 3.47 0.0011 90.00 100.00
PPExc 0.53 0.03 0.47 0.59 -0.03 -4.76 0.0016 83.60 100.00
PPcens 0.58 0.03 0.52 0.64 0.02 4.18 0.0015 89.90 100.00
IPCW 0.54 0.03 0.47 0.61 -0.02 -3.52 0.0012 95.80 100.00
IPCWn 0.54 0.03 0.47 0.61 -0.02 -3.53 0.0012 95.40 100.00
Weib2m 0.56 0.03 0.55 0.58 0.01 1.02 0.0008 35.10 100.00
Gam2m 0.56 0.03 0.55 0.58 0.01 1.03 0.0008 36.50 100.00
RPSFTM 0.56 0.03 0.49 0.63 0.00 -0.17 0.0008 97.90 100.00
IPE 0.55 0.03 0.49 0.63 0.00 -0.31 0.0008 97.90 100.00
IPEexp 0.55 0.03 0.49 0.63 0.00 -0.33 0.0008 98.10 100.00
Scenario number: 7
True mean survival:
Control: 0.64
Experimental: 0.74
Mean switch: 25.87%
True ave. HR: 0.76
Mean censored: 15.15%
Treatment effect:
20% decrement
ITT 0.65 0.03 0.59 0.72 0.01 1.69 0.0012 94.50 100.00
PPExc 0.62 0.04 0.55 0.69 -0.02 -3.10 0.0018 88.70 100.00
PPcens 0.68 0.04 0.61 0.75 0.04 6.19 0.0029 82.00 100.00
IPCW 0.64 0.04 0.56 0.73 0.00 -0.15 0.0014 98.20 100.00
IPCWn 0.64 0.04 0.56 0.73 0.00 -0.21 0.0014 98.10 100.00
Weib2m 0.65 0.03 0.63 0.66 0.00 0.63 0.0012 33.50 100.00
Gam2m 0.65 0.03 0.63 0.66 0.00 0.59 0.0012 33.60 100.00
RPSFTM 0.64 0.04 0.57 0.72 0.00 -0.17 0.0014 96.80 100.00
IPE 0.64 0.04 0.56 0.72 0.00 -0.29 0.0014 96.40 100.00
IPEexp 0.64 0.04 0.56 0.72 0.00 -0.30 0.0014 96.50 100.00
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the control group as a whole). Scenarios 5, 7, 13 and 15 are similar to Scenarios 1, 3, 9 and 11, respectively, with
the only substantive difference the switching proportion.
The reduced switching proportion has a limited impact on the bias, coverage and convergence associated with
the adjustment methods. The bias associated with the IPCW methods seemed slightly more sensitive to the
reduction in the switching proportion than the other adjustment methods: in Scenarios 7 and 15 the bias
associated with the IPCW and IPCWn methods decreased compared to Scenarios 3 and 11, whereas in
Scenarios 5 and 13 the opposite was true compared to Scenarios 1 and 9. The percentage bias of the Weib2m
and Gam2m methods generally marginally increased in these scenarios and coverage remained poor. The
percentage bias of the RPSFTM/IPE methods generally marginally reduced and coverage improved, suggesting
that the performance of these methods is improved in scenarios with lower switching proportions. All complex
adjustment methods continued to produce lower bias than the ITT analysis, with the exception of the IPCW and
IPCWn methods, which produced marginally more bias than the ITT analyses in Scenarios 5 and 13.
4.3 Other base scenarios
The results presented in Sections 4.1 and 4.2 provide a clear illustration of our key findings. Across all of these
scenarios the complex adjustment methods generally performed well, with percentage bias usually below 1.0%,
with the possible exception of the IPCW and IPCWn methods in scenarios where the treatment effect is high
(in which percentage bias increased to 2–4%).
In the other base scenarios (i.e. the first 16 scenarios detailed in Appendix 3) the pattern of the results remained
similar – PPcens and PPexc approaches generated very high levels of bias; RPSFTM, IPE and IPEexp methods
produced low bias – in particular when the ‘common treatment effect’ assumption held; the Weib2m and Gam2m
methods produced generally low levels of bias across all scenarios; IPCW and IPCWn methods generally produced
lower levels of bias than the ITT analysis and sometimes produced similar levels of bias to the RPSFTM, IPE and
IPEexp methods in scenarios where the common treatment effect assumption did not hold, but percentage bias
fluctuated more between scenarios. Percentage bias is presented for each method across each of the scenarios in
Appendix 4.
Across Scenarios 1–16 the percentage bias associated with the RPSFTM, IPE and IPEexp methods generally
more than doubled in scenarios where the common treatment effect assumption did not hold. In contrast,
percentage bias was approximately quartered in scenarios where the switching proportion was reduced from 30
to 44% of the control group to 13–18%.
It is notable that in all scenarios the RPSFTM, IPE and IPEexp methods led to negative bias – that is they over-
adjusted for the treatment switching effect. Such a pattern was not clear for the IPCW, IPCWn, Weib2m and
Gam2m methods, with bias fluctuating between positive and negative.
For the IPCW and IPCWn, the switching proportion and the size of the treatment effect were the most important
factors for performance. Appendix 4 illustrates that for the IPCW, percentage bias generally reduced when the
switching proportion was reduced from 30 to 44% of the control group (equivalent to approximately 60% of ‘at-risk’
patients) to 13–18% (equivalent to approximately 25% of ‘at-risk’ patients) (compare Scenarios 1–4 and 9–12 to
Scenarios 5–8 and 13–16) – although this pattern was not wholly consistent. Percentage bias also reduced in scenarios
where the treatment effect was reduced (Scenarios 3, 4, 7, 8, 11, 12, 15 and 16 compared to Scenarios 1, 2, 5, 6, 9, 10,
13 and 14). The IPCW and IPCWn methods usually produced higher levels of bias than the randomisation-based
methods, although this was often only marginal. Across Scenarios 1–8, in which the common treatment effect
assumption did not hold, the IPCW and IPCWn methods produced lower bias than the RPSFTM in three.
The two-stage adjustment methods (Weib2m and Gam2m) were less sensitive to the scenario parameters than
the other adjustment methods, with neither the switch proportion nor the treatment effect substantially affecting
bias across Scenarios 1–16.
Across Scenarios 1–16, the Gam2m method produced least percentage bias in six scenarios, and the Weib2m
produced least percentage bias in three scenarios. The RPSFTM produced least percentage bias in four scenarios
and the IPE produced least percentage bias in one scenario. The IPCW and IPCWn methods produced least
percentage bias in one scenario apiece. The ITT, PPexc and PPcens never produced least percentage bias.
4.4 Impact of sample size
Scenarios 17–32 replicated Scenarios 1–16, but with the sample size simulated in each scenario reduced to 300. We
anticipated that this would cause a worsening in the performance of the adjustment methods, particularly for the
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IPCW and IPCWn due to their observational basis. As illustrated by Appendix 4, in fact, there was a marginal
increase in bias for all methods, and the increase was not substantially greater for the IPCW approaches when
compared to the RPSFTM, IPE and IPEexp. Coverage in Scenarios 1–16 and Scenarios 17–32 was similar, with a
marginal increase in the scenarios with smaller sample size, reflecting slightly wider CIs. Reduced sample size led to
convergence problems for the IPCW, IPCWn and Gam2m methods, with convergence of the Gam2m falling to
88.1% in these scenarios (compared to 98.8% in Scenarios 1–16).
4.5 Impact of disease severity
Scenarios with an odd number simulated a severe disease and an administrative censoring proportion of
approximately 15%, whereas scenarios with an even number simulated moderate disease, with an administrative
censoring proportion of approximately 55%. It was difficult to identify the specific effect that increases in disease
severity and changing censoring proportions had on the performance of the adjustment methods, because a
consequence of a decreased disease severity and an increased censoring proportion was that a lower number of
control group patients were simulated to switch treatments – which itself is likely to influence method performance.
However, for most of the complex adjustment methods (with the exception of the IPCWn, Weib2m and Gam2m)
percentage bias generally marginally increased in scenarios with lower disease severity and consequent higher
censoring proportions, despite the lower overall switching proportion in these scenarios. For the IPCW, IPCWn
and particularly for the Gam2m there was a trend towards marginally poorer convergence in scenarios with lower
disease severity and higher censoring proportions.
4.6 Impact of the data generation model
Scenarios 33–64 replicated Scenarios 1–32, replacing the two-component mixture Weibull baseline hazard
function data generation model with a two-component mixture Gompertz baseline hazard function data
generation model. Apart from the underlying hazard function, these scenarios were similar (see Appendix 3 for
details). We found that the performance of the adjustment methods in Scenarios 33–64 was very similar to that
observed in Scenarios 1–32.
4.7 Extreme switching proportions
Scenarios 65–68 replicated Scenarios 1–4, but incorporated a very high switching proportion (47–70% of all control
group patients, equivalent to 94–95% of ‘at-risk’ patients). The extreme increase in switching proportion increased
the bias associated with all adjustment methods, as illustrated in Appendix 4. This increase was much more
substantial for the IPCW method than all other methods, and in three of the four scenarios the IPCW method
produced more bias than the ITT analysis. Notably, the percentage bias associated with the IPCWn method did not
increase substantially in Scenarios 65–68. This is because the IPCWn method does not take into account the ‘choice’
covariate, whereas the IPCW method does. In Scenarios 65–68, the number of control group patients who were at
risk of switching but did not switch ranged between 4 and 8 for the IPCW method, whereas for the IPCWn method
this number ranged between 25 and 40 because all control group patients were included in the risk set, rather than
only those with a ‘choice’ covariate value of ‘1’. The results of Scenarios 65–68, and those of our previous study,2
demonstrate that the IPCW method is prone to substantial error when the switching proportion amongst those
at risk of switching is very high (in excess of 90%), leaving very few at-risk patients who do not switch: in Scenarios
65–68, this was the case for the risk set defined by the IPCW method, but not for the risk set defined by the IPCWn
method. In fact, in these scenarios, the IPCWn method produced least percentage bias in two of the four scenarios,
with the Weib2m method producing least percentage bias in the remaining two scenarios.
5 Discussion
Our simulation study demonstrates that complex statistical adjustment methods produce low bias in a wide
range of scenarios, provided switching proportions are low or moderate. The complex adjustment methods
produced estimates of the comparative treatment effect that were closer to the truth than the ITT analysis,
whilst the naı¨ve adjustment methods produced substantially higher levels of bias. In general, the results of
the current study support the findings of our previous study.2 However, important new information has
been obtained. In particular, by comparing the results of the current study with those of our previous study,
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we can show that it is important to assess the magnitude of the average treatment effect in terms of an AF rather
than a HR. In general, the current study has provided more information on the key factors that influence the
performance of adjustment methods; this can be used to assist in the process of determining which adjustment
methods are likely to be appropriate on a case-by-case basis. These issues are discussed below.
In our previous study we often found levels of percentage bias of between 5 and 10%, or even higher
in scenarios with high switching proportions or where the common treatment effect assumption did not hold.2
In the current study, levels of percentage bias rarely exceeded 2–3% across all scenarios except those
that incorporated extreme switching proportions. This is partly because in our previous study half of the
72 scenarios run included extremely high switching proportions, compared to only four scenarios in the current
study. However, we believe this is also due to the different data-generating mechanism used in the current study,
which led to different survival time distributions and different treatment effects when measured on the AFT scale.
Although we cannot summarise the treatment effect simulated in either of our studies by a single value, because
the treatment effect varies as a function of time, we can estimate what the HR or AF would be assuming
proportional hazards or a constant AF, even though neither of these assumptions is true in our simulation
models. Taking this approach, we find that we simulated similar average HRs in the two studies, but average
AFs were very different. For example, in our previous study the average AF across the 72 scenarios varied between
1.44 and 3.58 and was over 2.0 in 60 of the 72 scenarios. In the current study, the AF across Scenarios 1–32 ranged
between 1.22 and 1.78. This is of importance for two reasons. First, the performance of each of the adjustment
methods is affected by the size of the treatment effect – particularly the IPCW methods, which produce more bias
when the treatment effect is higher. Therefore, the lower biases found in the current study may be expected.
Second, in the scenarios that violated the common treatment effect assumption, the decrement in the treatment
effect received by switchers was calculated as a proportion of the average AF in the experimental group. When this
AF is lower, a lower absolute decrement in the treatment effect will be applied to switchers, given the
same proportional decrement. This is highly likely to explain why the randomisation-based methods were much
less sensitive to departures from the common treatment effect assumption in the current study – it is the absolute
difference in the AF between switchers and patients randomised to the experimental group that determines
the subsequent bias of these methods. Generally, treatment effects in clinical trials are estimated in terms of a
HR, but, our results show that when assessing the potential bias associated with the application of adjustment
methods, it is important to also assess the size of the treatment effect in terms of an AF.
Whilst the current study suggests that complex statistical methods to adjust for treatment switching are
generally stable and prone to low levels of bias in situations when switching proportions are moderate or low,
within these scenarios important variations in the performance of methods arise – and the optimal adjustment
method changes. Simple adjustment methods (PPexc and PPcens) should be avoided, since these produce higher
bias than all of the other adjustment methods and the ITT analysis across all scenarios. The Gam2m and Weib2m
generally produced least bias, unless the common treatment effect assumption held and the switching proportion
was low, in which case the RPSFTM, IPE and IPEexp methods were often preferable. Taking the results of the
current study together with the results of our previous study,2 we know that the randomisation-based methods are
prone to higher levels of bias when the common treatment effect assumption does not hold, and when the AF
associated with the new treatment is relatively high (for instance, greater than 2.0). We also know that the two-
stage adjustment method is well suited to the scenarios simulated, because switching always occurred relatively
soon after the disease progression secondary baseline. Our study results suggest that in real-world situations the
randomisation-based methods and two-stage approach should be preferred when they are well suited to the
characteristics of the trial under investigation. Where the common treatment effect assumption is implausible,
the AF is high and there is no suitable secondary baseline, the IPCW method represents an adjustment method
that is likely to produce lower bias than the ITT analysis, provided the switching proportion is not extreme (greater
than 20 ‘at-risk’ patients remain ‘unswitched’) and no important prognostic covariates are missing.
However, circumstances remain in which adjustment methods may not improve upon the ITT analysis,
particularly if we consider the results of the present study alongside those of our previous study.
In the current study, the IPCW and IPCWn methods produced less bias than the ITT analysis in 70 and 75% of
scenarios, respectively, excluding the four scenarios in which the switching proportion was extremely high – in
which the IPCW method performed poorly. The ITT analysis produced less bias than the IPCW and IPCWn
methods in some scenarios in which the administrative censoring proportion was high (causing the adjustment
methods to work slightly less well) combined with a relatively low treatment effect (meaning the bias associated
with the ITT was relatively low), or when the treatment effect was higher (which led to more bias in the IPCW
analyses) combined with a low switching proportion (which led to less bias in the ITT analysis). When attempting
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to determine whether an IPCW analysis is likely to provide less bias than an ITT analysis in reality, a combination
of factors must be taken into account, including data availability, switching proportion, treatment effect size and
censoring proportion. When applying the IPCW, it should also be noted that it is only necessary to include
covariates that predict switching and survival. The current study showed that there was no appreciable
advantage to including the ‘choice’ covariate in the IPCW analysis, and in fact this led to substantially more
bias when extreme proportions switched. Including additional covariates increases the likelihood of obtaining
extreme weights and does not improve the performance of the adjustment if the additional covariates are not
prognostic. In addition, it should be considered that the IPCW approach does not take into account events that
may occur outside the trial in question, which could influence the probability of switching within the trial.
For instance, new evidence on the effectiveness of a similar treatment in a particular group of patients may
alter the pattern of switching in the trial in question, which could affect the ability of the method to accurately
predict the probability of switching.
The randomisation-based methods produced less bias than the ITT analysis across all scenarios in the current
study, despite the inclusion of scenarios that violated the common treatment effect assumption. This is an
important result that should increase confidence in these methods. However, this should be interpreted with
some caution, given that our previous study demonstrated that when the AF is high (greater than 2.0) the
potential for bias due to violations of the common treatment effect assumption is much greater. Hence, the size
of the AF and the plausibility of the common treatment effect assumption must be investigated when considering
the use of these methods. In addition, it should be noted that these methods produce decreased bias when the
switching proportion is low.
The two-stage adjustment methods produced less bias than the ITT analysis in 93% of the scenarios included in
the current study, often produced least bias of all the adjustment methods and were much less sensitive to the
scenario parameters than the other adjustment methods. The Gam2m method generally produced marginally
lower bias than the Weib2m – which may be expected given the greater flexibility of the three-parameter
generalised Gamma model – but experienced some convergence issues when the sample size was 300, and when
the proportion of administrative censoring was high. In practice, the AFT model used within the two-stage
estimation method should be determined through a consideration of which model best fits the data. The two-
stage adjustment methods were less likely to produce least bias in scenarios in which the common treatment effect
assumption held and there was a lower switching proportion – in these scenarios it was more common for the
randomisation-based methods to produce least bias. Therefore, again, several trial characteristics must be taken
into account when considering the utility of applying two-stage adjustment methods to trials affected by treatment
switching.
Based upon our study, it is not possible to predict the direction of bias associated with the adjustment methods.
The randomisation-based methods always produced negative bias – that is they over-adjusted for the treatment
switching effect, but this is likely to be due to the scenarios simulated. Where switchers receive a lower treatment
effect than patients in the experimental group, the common treatment effect assumption associated with the
RPSFTM and IPE methods will result in the survival times of switchers being over-adjusted. In addition,
recensoring involves basing the treatment effect estimation upon shorter term data, and where the experimental
group treatment effect decreases over time (as it did in our study) this may lead to an over-estimate of the true
treatment effect. However, bias in the opposite direction may result if the treatment effect increases over time, or if
switchers receive an enhanced treatment effect, which could conceivably be the case in the real world if patients
who switched were those most likely to benefit from the experimental treatment. Patterns in the direction of bias
were not observed for the IPCW and two-stage adjustment methods.
6 Limitations
A limitation associated with any simulation study is that not all scenarios that may be observed in practice can be
investigated. We attempted to include all the most important and most relevant scenarios given the scenario
coverage and results of our previous study, realistic cancer trial characteristics and the characteristics of the
methods we were assessing. However, there remain further questions that would be useful to investigate – both
through further simulations, and through other methodological research.
For instance, we found that the randomisation-based methods were much more robust to departures from the
common treatment effect assumption in this study, compared to our previous study.2 This is highly likely to be due
to the difference in the size of the AFs simulated in the two studies. Often AFs are not reported in clinical study
reports, and it would be of value to analyse real-world datasets in order to determine realistic AF sizes, in order
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that we can better understand the potential problems caused by departures from the common treatment effect
assumption in the real world. In reality, the common treatment effect assumption inhibits the confidence that
decision-makers have in randomisation-based methods.40 Whilst our study provides useful information on the
potential bias caused by violations of this assumption, further research into methods that may be used in an
attempt to test its validity would be of great value.
Also, our study only considers switching from the control group onto the experimental treatment. In practice,
other switches could occur – for example, patients in either group could switch onto other (non-standard)
treatments.40 The one-parameter RPSFTM would not be appropriate to adjust for this type of switching,
though variations of the IPCW and two-stage adjustment methods could be used. Further research in this area
would be valuable.
In our study, we incorporated recensoring within the RPSFTM, IPE, IPEexp and two-stage adjustment
methods. Recensoring is recommended when methods involve the estimation of counterfactual censoring
times.37–39 However, when the treatment effect is not constant, recensoring may lead to biased estimates of the
treatment effect, because estimates are not based upon the full duration of the clinical trial. In our study, it was not
possible to distinguish between bias caused by recensoring and bias related to violations of the common treatment
effect assumption. In some situations, it may actually be preferable not to recensor: further research on the impact
of recensoring and when it is and is not appropriate would be valuable.
Between our previous study and our current study we have gathered useful information regarding
what number of ‘at-risk’ patients in the control group who do not switch treatments is required in order for
the IPCW to produce low levels of bias. It seems that this number is likely to be in the region of 20, but
it would be useful to run further scenarios with different sample sizes and switching proportions aimed
specifically at providing more information on this. From a practical perspective, this would provide useful
guidance to analysts.
In addition, we used a similar approach to simulate survival data and varying treatment effects to that used
in our previous study – although more complex models were used. It is difficult to simulate such data in a
biologically plausible way, and this represents a limitation of our study. Linked to this, we simulated a
treatment effect that decreased over time in the experimental group, but the effect applied to switchers was
not linked to time: instead the baseline treatment effect was multiplied by a factor to ensure that these
patients received a plausible effect. Alternative approaches are possible – the effect received could have
been linked in some way to time or other covariates. However – as argued in our previous study report2 –
this would not be expected to alter the results of the study because of the way the adjustment methods work.
The IPCW censors patients at switch, and therefore the effect received by these patients is irrelevant,
whereas for the randomisation-based methods the important determinant of bias is the extent to which the
average treatment effect differs between switching and experimental group patients – not how this treatment
effect difference is estimated.
Because we simulated a treatment effect that changed over time, there was not a single ‘true’ HR, or AF, in any
of the scenarios simulated. Instead, we used restricted mean survival time at 18 months as our ‘true’ statistic,
against which adjustment methods were compared. Because this is one step removed from the treatment effect
estimated directly by each of the adjustment methods, this may be regarded as a limitation of the study. However,
in practice, adjustment methods have been most regularly used by HTA agencies,40 for whom mean survival times
are of paramount importance.7 Therefore, our use of mean survival estimates is useful. In addition, our use of a
restricted mean meant that resulting bias is associated with the adjustment methods rather than any extrapolation
approach, and we used consistent approaches to estimate restricted mean survival for each adjustment method in
order to avoid biasing our results.
A general limitation of simulation studies is that the results are likely to always be linked in some way to the
chosen data-generating process. However, we have gone some way to demonstrating that this is not the case in this
study, since we tested each scenario using two different data-generating models. In addition, our results generally
support those found in our previous study,2 which used a different data-generating model.
Finally, our previous study and our current study give us confidence that the two-stage adjustment
method represents a potentially valuable method for adjusting for treatment switching. However, so far we have
only tested this method in scenarios where switching happens soon after the ‘secondary baseline’ of
disease progression. It would be valuable to identify how sensitive this method is to switching that occurs further
from the secondary baseline time point. In addition, in practice, bootstrapping should be used to estimate CIs
associated with the two-stage method, but doing so in a simulation study would be extremely computationally
expensive – therefore we have not tested the coverage associated with the preferred application of the method.
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7 Conclusions
When treatment switching occurs in clinical trials complex adjustment methods such as the RPSFTM, IPE, IPCW
and two-stage adjustment are likely to provide close approximations of the true treatment effect, provided the
switching proportion is moderate (less than approximately 60% of control group patients who became eligible to
switch). They are likely to provide a closer approximation of the true treatment effect than an ITT analysis. This is
the case for RPSFTM and IPE approaches even if the common treatment effect assumption is false, provided the
AF is less than approximately 2.0 – although this is also dependent upon the absolute difference between the
treatment effect received by switchers and that received by patients initially randomised to the experimental group.
The IPCW produces more variable results and is prone to substantial error when the switching proportion is very
high (leaving less than 20 control group patients who became eligible to switch yet did not). Simple two-stage
adjustment methods, using Weibull or generalised Gamma models, are less sensitive to factors such as the
switching proportion and the treatment effect (and whether it is ‘common’), and are often likely to produce
very low levels of bias provided that a suitable secondary baseline exists. Our study provides further evidence
that appropriate methods for adjusting for treatment switching should be identified on a case-by-case basis, taking
into account the characteristics of the trial and therapy under investigation, as suggested by Latimer et al.1
RPSFTM, IPE, IPCW and two-stage methods should be considered and, where appropriate, presented
alongside the ITT analysis. Simple PP analyses should ordinarily not be considered.
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